Development and biological evaluation of <sup>90</sup>Y-BPAMD as a novel bone seeking therapeutic Agent

Rabiei, Ali; Shamsaei, Mojtaba; Yousefnia, Hassan; Zolghadri, Samaneh; Jalilian, Amir Reza; Enayati, Razieh

doi:10.1515/ract-2015-2561

Cited by 3 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…90 Y-BPAMD was prepared according to the previously reported literature. 18 Briefly, 1 mg of BPAMD was dissolved in 1 mL pure water and the aqueous solution was used for labelling studies. 60 μL (105 nmol) of the stock solution was added to the vial containing 370 MBq of 90 YCl 3 .…”

Section: Preparation and Quality Control Of 90 Y-bpamdmentioning

confidence: 99%

See 1 more Smart Citation

Preliminary dosimetric evaluation of ⁹⁰Y-BPAMD as a potential agent for bone marrow ablative therapy

Rabiei

Yousefnia²,

Zolghadri³

et al. 2018

J Radiother Pract

Self Cite

View full text Add to dashboard Cite

AimBone-seeking radiopharmaceuticals are potential therapeutic tools for bone marrow ablation in patients with multiple myeloma. In this procedure, estimation of radiation absorbed dose received by the target and non-target organs is one of the most important parameters that should be undertaken. This research revolves around the absorbed dose to human organs after 90Y-BPAMD injection.Materials and methods90Y-(4-{[(bis(phosphonomethyl))carbamoyl]methyl}-7,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl) acetic acid (90Y-BPAMD) complex was successfully prepared under optimised conditions. The human absorbed dose of the complex was estimated based on the biodistribution data on rats using the radiation-absorbed dose-assessment resource method. The target to non-target absorbed dose ratios for the complex was compared with the ratios for 166Ho-DOTMP, as the main radiopharmaceutical for bone marrow ablation.ResultsAs expected, the highest amounts of absorbed dose were observed in the bone surface and the bone marrow with 2·52 and 2·29 mGy/MBq, respectively. The red marrow to the most organ absorbed dose ratios for 90Y-BPAMD are much higher than the ratios for 166Ho-DOTMP.Findings90Y-BPAMD has interesting characteristics compared with 166Ho-DOTMP and can be considered as a high potential agent for bone marrow ablative therapy of the patient with multiple myeloma.

show abstract

Section: Preparation and Quality Control Of 90 Y-bpamdmentioning

confidence: 99%

“…, 17 These complexes suffer from the low stability in human serum resulting in the liver toxicity. Recently, 90 Y-BPAMD was prepared that showed interesting characteristics compared with the other 90 Y bone-seeking agents and even 166 Ho-BPAMD 18 …”

Section: Introductionmentioning

confidence: 99%

Preliminary dosimetric evaluation of ⁹⁰Y-BPAMD as a potential agent for bone marrow ablative therapy

Rabiei

Yousefnia²,

Zolghadri³

et al. 2018

J Radiother Pract

Self Cite

View full text Add to dashboard Cite

show abstract

Nano Yttrium-90 and Rhenium-188 production through medium medical cyclotron and research reactor for therapeutic usages: A Simulation study

Khorshidi

2023

Nuclear Engineering and Technology

View full text Add to dashboard Cite

Development of [⁶⁴Cu]Cu-BPAMD for PET imaging of bone metastases

Zolghadri,

Badipa,

Yousefnia

et al. 2024

Radiochimica Acta

View full text Add to dashboard Cite

In this study, preclinical evaluation and dosimetric estimation of [64Cu]Cu-BPAMD, as a new bone-seeking agent for PET imaging, was studied. [64Cu]Cu-BPAMD was produced with a specific activity of 8.7 GBq/µmol and radiochemical purity (R.P.) of >98 %. The HA binding results showed the binding of nearly all [64Cu]Cu-BPAMD complex to HA at about 15 mg. Biodistribution studies in the male Syrian rats indicated considerable accumulation in the bone with negligible uptake in the other organs. The bone surface and the bone marrow receiving 0.199 and 0.092 mGy/MBq, respectively, are the organs with the most absorbed dose. This study confirms the production of [64Cu]Cu-BPAMD with high R.P. showing high potential for PET-imaging of bone metastases. The lower absorbed dose of mainly human organs compared to 68Ga-BPAMD can be considered one of the advantages of this new radiolabeled compound.

show abstract

Development and biological evaluation of ⁹⁰Y-BPAMD as a novel bone seeking therapeutic Agent

Cited by 3 publications

References 16 publications

Preliminary dosimetric evaluation of ⁹⁰Y-BPAMD as a potential agent for bone marrow ablative therapy

Preliminary dosimetric evaluation of ⁹⁰Y-BPAMD as a potential agent for bone marrow ablative therapy

Nano Yttrium-90 and Rhenium-188 production through medium medical cyclotron and research reactor for therapeutic usages: A Simulation study

Development of [⁶⁴Cu]Cu-BPAMD for PET imaging of bone metastases

Contact Info

Product

Resources

About

Development and biological evaluation of 90Y-BPAMD as a novel bone seeking therapeutic Agent

Cited by 3 publications

References 16 publications

Preliminary dosimetric evaluation of 90Y-BPAMD as a potential agent for bone marrow ablative therapy

Preliminary dosimetric evaluation of 90Y-BPAMD as a potential agent for bone marrow ablative therapy

Nano Yttrium-90 and Rhenium-188 production through medium medical cyclotron and research reactor for therapeutic usages: A Simulation study

Development of [64Cu]Cu-BPAMD for PET imaging of bone metastases

Contact Info

Product

Resources

About

Development and biological evaluation of ⁹⁰Y-BPAMD as a novel bone seeking therapeutic Agent

Preliminary dosimetric evaluation of ⁹⁰Y-BPAMD as a potential agent for bone marrow ablative therapy

Preliminary dosimetric evaluation of ⁹⁰Y-BPAMD as a potential agent for bone marrow ablative therapy

Development of [⁶⁴Cu]Cu-BPAMD for PET imaging of bone metastases